Skip to main content
SpringerLink
Log in

Matrix metalloproteinase inhibitors: Present achievements and future prospects

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Matrix metalloproteinases (MMPs) are a class of structurally related enzymes that function in the degradation of extracellular matrix proteins that constitute the pericellular connective tissue and play an important role in both normal and pathological tissue remodelling. Increased MMP activity is detected in a wide range of cancers and seems correlated to their invasive and metastatic potential. MMPs thus seem an attractive target for both diagnostic and therapeutic purposes.

Several synthetic matrix metalloproteinase inhibitors (MMPIs) are currently being developed. Preclinical studies are promising as they suggest inhibition of several steps in the metastatic process. Marimastat is the first MMPI to enter comparative phase III trials after early clinical trials established the safety profile. Clinical trials will need to be specifically designed to optimally evaluate the therapeutic potential of this novel class of cytostatic drugs. Safety studies should consider the markedly different toxicity profile and determine the range of biologically active dosage, while efficacy studies should be performed in selected clinical settings with appropriate end-points. We review the present achievements in preclinical and clinical studies with MMPIs, discuss specific considerations for appropriate study design and reflect on the future prospects of this novel class of agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mignatti P, Isubio T, Robbins E, Rifkin DB: In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biology 108: 671–682, 1989.

    Google Scholar 

  2. Declerck YA, Imren S: Protease inhibitors: Role and potential therapeutic use in human cancer. Eur J Cancer 30A: 2170–2180, 1994.

    Google Scholar 

  3. Miller LB: Structure and function of the urokinase receptor. Blood coagul. Fibrinolysis 4: 292–303, 1993.

    Google Scholar 

  4. Ellis V, Pyke C, Eriksen J, Solberg H, Dano K: The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann NY Acid Sci 667: 13–31, 1992.

    Google Scholar 

  5. Gross J, Lapiere CM: Collagenolytic activity in amphibian tissues: a tissue cultur assay. Proc Natl Acad Sci 48: 1014–1022, 1962.

    Google Scholar 

  6. Stetler-Stevenson WG, Krutzsch HC, Wacher MP, Margulies MK, Liotta L: The activity of human type IV colagenase proenzyme. J Biol Chem 264: 1353–1356, 1989a.

    Google Scholar 

  7. Wilhelm SM, Eisen AZ, Teter M, Clark SD, Kronberger A, Goldberg G: Human fibroblast collagenase: Glycosylation and tissue-specific levels of enzyme synthesis. Proc Natl Acad Sci 83: 3756–3760, 1986.

    Google Scholar 

  8. Muller D, Quantin B, Gesnel MC, Millon-Collard R, Abecassis J, Breathnach R: The collagenase gene family in humans consist of at least four members. Biochem J 253: 187–192, 1988.

    Google Scholar 

  9. Hasty KA, Pourmotabbed TF, Goldberg GI, Thompson JP, Spinella DG, Stevens RM, Mainardi CI: Human neutrophil collagenase. J Biol Chem 265: 11421–11424, 1990.

    Google Scholar 

  10. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, Kronberger A, He C, Bauer EA, Goldberg GI: H-ras oncogene-transformed human bronchial epthelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 263: 6579–6587, 1988.

    Google Scholar 

  11. Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI: SV40-transformed human lung fibroblasts secrete a 92 kDa Type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 264: 17213–17221, 1989.

    Google Scholar 

  12. Welgus HG, Fliszar CJ, Seltzer JL, Schmid TM, Jeffrey JJ: Differential susceptibility of type X collagen to cleavage by two mammalian interstitial collagenases and 72 kDa type IV collagenase. J Biol Chem 265: 13521–13527, 1990.

    Google Scholar 

  13. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG: Human 92-and 72-kilodalton type IV collagenases are elastases. J Biol Chem 266: 7870–7875, 1991.

    Google Scholar 

  14. Wilhelm SM, Collier IE, Kronberger A, Eisen AZ, Marmer BL, Grant GG, Bauer EA, Goldberg GI: Human skin fibroblast stromelysins: Structure, glycosylation, substrate specificity, and differentiat expression in normal and tumourigenic cells. Proc Natl Acad Sci 84: 6725–6729, 1987.

    Google Scholar 

  15. Nicholson R, Murphy G, Breathnach R: Human and rat malignant-tumour-associated mRNAs encode stromelysin-like metalloproteinases. Biochemistry 28: 5195–5203.

  16. Quantin B, Murphy G, Breathnach R: Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members. Biochemistry 28: 5325–5334, 1989.

    Google Scholar 

  17. Wu J-J, Lark MW, Chun LE, Eyre DR: Sites of stromelysin cleavage in collagen types II, IX, X and XI of cartilage. J Biol Chem 266: 5625–5628, 1991.

    Google Scholar 

  18. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Poldhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348: 699–7-4, 1990.

    Google Scholar 

  19. Murphy GJP, Murphy G, Reynolds JJ: The origin of matrix metalloproteinases and their familial relationships. FEBS Lett 289: 4–7, 1991a.

    Google Scholar 

  20. Sato H, Takino T, Okada Y: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 61–65, 1994.

    Google Scholar 

  21. Strongin A, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72 kDa type IV collagenase. J Biol Chem 270: 5331–5338, 1995.

    Google Scholar 

  22. Takino T, Sato H, Shinagawa A, Seiki M: Identification of the second membrane-type matrix metalloproteinase (MT-MMP2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem 270: 23013–23020, 1995.

    Google Scholar 

  23. Poulson R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcroft JM, Rogers L, Stamp GW: STromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 141: 389–396, 1992.

    Google Scholar 

  24. Stetler-Stevenson WG, Aznavoorian S, Liotta L: Tumor cell interactions with the extracellular matrix during invasion and metastases. Ann Rev Cell Biol 4: 541–573, 1993.

    Google Scholar 

  25. Karelina TB, Hruza GJ, Goldberg GI, Eisen AZ: Location of 92-KDA type IV collagenase in human skin tumors: comparison with normal human fetal and adult skin. J Invest Dermatol 100: 159–165, 1993.

    Google Scholar 

  26. Nabeshima K, Lane WS, Biswas C: Partial sequencing and characterization of the tumor cell-derived collagenase stimulatory factor. Arch Biochem Biophys 285: 90–96, 1994.

    Google Scholar 

  27. Vassalli JD, Pepper MS: Tumourbiology. Membrane proteases in focus. Nature 370: 14–15, 1994.

    Google Scholar 

  28. Lee SW, Ellis V, Dichek DA: Characterization of plasminogen activation by glycosylphosphatidylinositol-anchored urokinase. J Biol Chem 269: 2411–2418, 1994.

    Google Scholar 

  29. Docherty AJP, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJR: Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 318: 66–69, 1985.

    Google Scholar 

  30. Stetler-Stevenson WG, Krutzsch HC, Liotta L: Tissue inhibitor of metalloproteinase (TIMP-2): A new member of the metalloproteinase inhibitor family. J Biol Chem 264: 17374–17378, 1989b.

    Google Scholar 

  31. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR: Tissue inhibitor of metalloproteinases-3 (TIMP-3) as an extracellular matrix-associated protein with ad distinctive pattern of expression in mouse cells and tissues. J Biol Chem 269: 9352–9360, 1994.

    Google Scholar 

  32. Firestein GS: Mechanisms of tissue destruction and cellular activation in rheumatoid arthritis. Curr Opin Rheumatol 4: 348–354, 1992.

    Google Scholar 

  33. Gijbels K, Masure S, Carton H, Opdenakker G: Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 41: 29–34, 1992.

    Google Scholar 

  34. Liotta LA, Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Sem Cancer Biol 1: 99–106, 1990.

    Google Scholar 

  35. Abramson M, Schilling RW, Huang C-C, Salome RG: Collagenase activity in epidermoid carcinoma of the oral cavity and larynx. Ann Otol Rhinol Laryngol 84: 158–163, 1975.

    Google Scholar 

  36. Kubochi K: New direct assay method of type IV collagenase in tissue homogenate and biochemical rol eof collagenase against type I, and IV collagens to the invasion of the stomach and lung cancer. Nippon Gelat Gakkan Zasski 91: 174–183, 1990.

    Google Scholar 

  37. Van der Stappen JWJ, Hendriks T, Wobbest T: Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int J Cancer 45: 1071–1078, 1990.

    Google Scholar 

  38. Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE, Turner DR: Distribution of colagenase and tissue inhibitor metalloproteinases (TIMP) in colorectal tumors. Int J Cancer 49: 666–672, 1991.

    Google Scholar 

  39. Polette M, Clavel C, Miller D, Abecassis J, Binninger I, Birembait P: Detection of mRNAs encoding collagenas I and stromelysin-2 in carcinomas of the head and neck by in situ hybridization. Metastasis 11: 76–83, 1991.

    Google Scholar 

  40. Siadat Pajouh M, Nagle BB, Breathnach R, Finch JS, Brawer MK, Bowden GT: Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 117: 144–150, 1991.

    Google Scholar 

  41. Muller D, Breathnach R, Engelmann A, Millon R, Bronner G, Flench H, Dumont P, Eber M, Abecassis J: Expression of colagenase-related metalloproteinase genes in human lung or head and neck tumors. Int J Cancer 48: 550–556, 1991.

    Google Scholar 

  42. McDonnel S, Navre M, Coffey RJ, Matrisian LM: Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric cancer and colon carcinomas. Molecular Carcinogenesis 4: 527–533, 1991.

    Google Scholar 

  43. Yoshimoto M, Itoh F, Yamamoto H, Himoda Y, Imai K, Yachi A: Expression of MMP-7 (Pump-1) mRNA in human colorectal cancers. Int J Cancer 54: 614–618, 1993.

    Google Scholar 

  44. Brown PD, Bloxidge RE, Anderson E, Howell A: Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 11: 183–190, 1993a.

    Google Scholar 

  45. Davies B, Miles DW, Happerfeild LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67: 1126–1131, 1993a.

    Google Scholar 

  46. D'Errico A, Garbina S, Liotta LA, Cantronovo V, Stetler-Stevenson WG, Grogioni WF: Augmentation of type IV collagenase, laminin receptor, and KI67 proliferation antigen associated with human colon, gastric and breast carcinoma progression. Mol Pathol 4: 239–246, 1991.

    Google Scholar 

  47. Daidone MG, Silvestrini R, D'Errico A, Di Fronzo G, Benini E, Mancini AM, Garbina S, Liotta L, Grigioni WF: Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer 48: 529–532, 1991.

    Google Scholar 

  48. Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA: Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Path 16: 500–507, 1992.

    Google Scholar 

  49. Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, Micela M, Steler-Stevenson WG, Liotta LA: Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 52: 548–549, 1992.

    Google Scholar 

  50. Brown PD, Bloxidge RE, Stuart NSA, Gatter KC, Carmichael J: Correlation between expression of activated 72 kDa gelatinase and tumour spread in non-small cell lung carcinoma. J Natl Cancer Inst 85: 574–578, 1993b.

    Google Scholar 

  51. Pyke C, Ralfklaer E, Huhtala P, Hurskainen T, Dano K, Tryggvason K: Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 52: 1336–1341, 1992.

    Google Scholar 

  52. Nomura H, Sato H, Seiki M, Mai M, Okada Y: Expression of the membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 55: 3263–3266, 1995.

    Google Scholar 

  53. Murphy G, Houbrechts A, Cockett MJ, Williamson RA, O'Shea, Docherty AJP: The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 30: 8097–8101, 1991b.

    Google Scholar 

  54. Declerck YA, Yean T-D, Lee Y, Tomich JM, Langley KE: Characterization of the functional domain of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochem J 289: 65–69, 1993a.

    Google Scholar 

  55. Schwartz MA, Venkataraman S, Chaffari MA, Libby A, Mookhtiar KA, Mallya SK, Birkedal-Hanssen H, van Wart HE: Inhibition of human collagenases by sulphur-base substrate analogs. Biochem Biophys Res Commun 176: 173–179, 1991.

    Google Scholar 

  56. Schultz RM, Silberman S, Persky B, Bajkowski AS, Carmichael DF: Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 48: 5539–5545, 1988.

    Google Scholar 

  57. Alvarez OA, Carmichael DF, Declerck YA: Inhibition of colagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 82: 589–595, 1990.

    Google Scholar 

  58. Reich R, Thompson EW, Iwalmoto Y, Martin GR, Deason JR, Fuller GC, Miskin R: Effects of inhibitors of plasminogen activator, serine proteinases and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 48: 3307–3312.

  59. Chirivi R, Garofalo A, Crimmin M, Bawden L, Brown P, Giavazzi R: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58: 460–464, 1994.

    Google Scholar 

  60. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD: Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56: 2815–2822, 1996.

    Google Scholar 

  61. Brown PD, Giavazzi R: Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 6: 967–974, 1995.

    Google Scholar 

  62. Declerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52: 701–708, 1992.

    Google Scholar 

  63. Davies B, Brown PD, East N, Balkwill FR: A synthetic metalloproteinase inhibitor decreases tumour burden and prolongs survival of mice with ovarian cancer xenografts. Cancer Res 53: 2087–2091, 1993b.

    Google Scholar 

  64. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD: Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 55: 3629–3633, 1995.

    Google Scholar 

  65. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54: 4726–4728, 1994.

    Google Scholar 

  66. Sledge Jr GW, Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Canc Inst 87: 1546–1550, 1995.

    Google Scholar 

  67. Watson SA, Morris TM, Parsons SL, Steele RJC, Brown PD: Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br J Cancer 74: 1354–1358, 1996.

    Google Scholar 

  68. Low JA, Johnson MD, Bone EA, Dickson RB: The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res 2: 1207–1214, 1996.

    Google Scholar 

  69. Anderson IC, Shipp MA, Docherty AJP, Teicher BA: Combination therapy including a gelatinase inhibitor and cytotoxic agents reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 53: 2087–2091, 1993.

    Google Scholar 

  70. Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 248: 1408–1410, 1990.

    Google Scholar 

  71. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR: Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Critical Rev in Oral Bio and Medicine 2: 297–322, 1991.

    Google Scholar 

  72. Beattie GJ, Young HA, Smyth JF: Phase I study of intraperitoneal metalloproteinase inhibitor BB-94 in patients with malignant ascites (Abstract). 8th NCI-EORTC Symposium on New Drug Development, Amsterdam, March 1994.

  73. Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A, Hawkins MJ: Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Inv New Drugs 14: 193–202, 1996b.

    Google Scholar 

  74. O'Byrne KJ, Macaulay VM, Long L, Propper D, Braybooke J, Gleeson F, Ganesan TS, Harris AL, Talbot DC: Phase I study of matrix metalloproteinase inhibitor batimastat in patients with malignant pleural effusions (Abstract). 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, March 1996.

  75. Grams F, Crimmin M, Hinnes L: Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochem 34: 14012–14040, 1995.

    Google Scholar 

  76. Becket RP, Davidson AH, Drummond AH, Huxley P, Whittaker M: Recent advances in matrix metalloproteinase inhibitor research. DDT 1: 16–26, 1996.

    Google Scholar 

  77. Wojtowics-Praga S, Low J, Dickson R, Ness E, Sale M, Rasmussen HS, McCann P, Hawkins M: Pharmacokinetics of marimastat, a novel matrix metalloproteinase inhibitor administered orally to patients with metastatic lung cancer (Abstract 1565). Proc Am Soc Clin Oncol 15: 490, 1996a.

    Google Scholar 

  78. Maltefano J, Teng N, Moore D, Barter J, Lopez A, Schink J, Cole A, Rasmussen H: Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced cancer of the ovary: a dose finding study (Abstract 764). Proc Am Soc Clin Oncol 15: 283, 1996.

    Google Scholar 

  79. Rosemurgy A, Harris J, Langleben A, Casper E, Allen R, Rasmussen H: Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas (Abstract 470). Proc Am Soc Clin Oncol 15: 207, 1996.

    Google Scholar 

  80. Boasberg P, Harbaugh B, Roth B, Eisenberger M, Langleben A, Allen R, Rasmussen H: Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone-refractory prostate cancer (Abstract 671). Proc Am Soc Clin Oncol 15: 258, 1996.

    Google Scholar 

  81. Poole C, Adams M, BArley V, Graham J, Kerr D, Louviaux I, Perren T, Piccart M, Thomas H: A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced ovarian cancer (Abstract 322). Ann Oncol 7(Suppl 5): 68, 1996.

    Google Scholar 

  82. Primrose J, Bleiberg H, Daniel F, Johnson P, Mansi J, Neoptolemos J, Seymour M, Van Beele S: A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced colorectal cancer (Abstract 159). Ann Oncol 7(Suppl 5): 35, 1996.

    Google Scholar 

  83. Evans J, Bramhall S, Carmichae J, Daniel F, Imrie C, Johnson C, Neoptolemos J, Stark A: A phase II study of marimastat in advanced pancreatic cancer (Abstract 239). Ann Oncol 7(Suppl 5): 51, 1996.

    Google Scholar 

  84. Parsons SL, Watson SA, Griffin NR, Steele RJC: An open phase I/II study of the oral matrix metalloproteinase inhibitor marimastat in patients with inoperable gastric cancer (Abstract 222). Ann Oncol 7(Suppl 5): 47, 1996.

    Google Scholar 

  85. Miller A, Brown P: 360 patient meta-analysis of studies of marimastat. A novel matrix metalloproteinase inhibitor (Abstract 594). Ann Oncol 7(Suppl 5): 123, 1996.

    Google Scholar 

  86. Talbot DC, Brown PD: Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32A: 2528–2533, 1996.

    Google Scholar 

  87. Greenwald RA: Guidelines for clinical trial design for evaluation of MMP inhibitors. Ann NY Acad Sci 732: 273–279, 1994.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, Rotterdam, The Netherlands

    L.J. Denis & J. Verweij

Authors
  1. L.J. Denis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Verweij
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Denis, L., Verweij, J. Matrix metalloproteinase inhibitors: Present achievements and future prospects. Invest New Drugs 15, 175–185 (1997). https://doi.org/10.1023/A:1005855905442

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005855905442

Search

Navigation